Editing Pemetrexed (section)

==Research==
A Phase III study showed benefits of maintenance use of pemetrexed for non-squamous NSCLC.<ref>{{cite journal | vauthors = Belani CP, Brodowicz T, Ciuleanu T, Kim JH, Krzakowski M, Laack E, Wu YL, Peterson P, Krejcy K, Zielinski C | display-authors = 6 
  | title = Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: A randomized phase III study in advanced non-small cell lung cancer (NSCLC). | journal = Journal of Clinical Oncology | date = June 2009 | volume = 27 | issue = 18 suppl | pages = CRA8000 | publisher = [[American Society of Clinical Oncology]] | doi = 10.1200/jco.2009.27.18_suppl.cra8000 
 | url = http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=33019 | access-date = 22 July 2009 | archive-date = 16 June 2009
| archive-url = https://web.archive.org/web/20090616132533/http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=33019 | url-status = dead | url-access = subscription }}</ref> Activity has been shown in malignant peritoneal mesothelioma.<ref>{{cite journal | vauthors = Carteni G, Manegold C, Garcia GM, Siena S, Zielinski CC, Amadori D, Liu Y, Blatter J, Visseren-Grul C, Stahel R | display-authors = 6 | title = Malignant peritoneal mesothelioma-Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent | journal = Lung Cancer | volume = 64 | issue = 2 | pages = 211–218 | date = May 2009 | pmid = 19042053 | doi = 10.1016/j.lungcan.2008.08.013 }}</ref>